ArticleAdvances in radiation oncology2026
Nonprostate Cancer Deaths Best Predict Long-Term Survival in Men Aged ≤59 Years Treated With Low Dose Rate Brachytherapy With or Without Supplemental Therapies: A Mandate for Health Enhancement.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Despite favorable biochemical and functional outcomes in younger patients treated with prostate brachytherapy, overall survival remains compromised by a plethora of nonprostate cancer deaths, especially those attributable to sedentary lifestyle or modifiable health risks. In this study, we evaluate cancer control and patterns of death and propose recommendations for lifestyle changes and aggressive management of medical comorbidities. Methods and Materials: A total of 782 consecutive men aged ≤59 years underwent brachytherapy with or without supplemental therapies. Patients were stratified into 2 age cohorts: ≤54 years (n = 331) and 55 to 59 years (n = 451). Postimplant dosimetry was based on the day 0 computed tomography evaluation. Biochemical failure (BF) was defined as prostate-specific-antigen (PSA) > 0.40 ng/mL after nadir. Patients with metastatic prostate cancer or nonmetastatic castrate-resistant disease who died of any cause were classified as deaths from prostate cancer. All other deaths were attributed to the immediate cause of death. Multiple clinical, pathologic, and treatment parameters were evaluated for their impact on survival. Results: No significant differences in presentation were observed between the 2 cohorts, except that hypertension and tobacco use were statistically more common in the 55- to 59-year-old age group. The median follow-up was 12.1 years. A total of 40.8% of patients presented with unfavorable intermediate- or high-risk disease. The median day 0 minimum dose of radiation to 90% of the prostate gland (D90) was 122.1%. For the entire cohort, the 15-year BF, prostate cancer-specific mortality, and overall mortality (OM) rates were 4.9%, 1.8%, and 16.5%, respectively. When stratified by age, the 15-year BF rates were 6.1% and 4.0% in the younger and older cohorts, respectively ( Conclusions: Brachytherapy generates favorable oncologic outcomes in younger men with prostate cancer. Nonprostate cancer deaths substantially outnumber prostate cancer deaths, with the majority due to cardiovascular disease or other malignancies. Improvement in overall survival will require multiple lifestyle changes and aggressive management of modifiable health risks.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.